events
Mark your calendar for November 19-21 and meet us at Fi Europe 2024, Messe Frankfurt, Germany. We look forward to connecting with you at this exciting event!
Learn More >>
Products

Enzymes for Research, Diagnostic and Industrial Use

Products
Online Inquiry

Our Products Cannot Be Used As Medicines Directly For Personal Use.

24 hour
Promise

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.

Reparixin L-lysine salt

Cat No.
CEI-1497
Product Overview
Reparixin L-lysine salt is an inhibitor of interleukin 8 receptor alpha (CXCR1) and beta (CXCR2) with IC50 value of 5.6 nM and 80 nM respectively. CXCR1 and 2 belong to class A of 7-transmembrane G protein coupled receptor, and they share 78% amino acid identity. They are specific receptors for interleukin-8 which is a chemokine. They are mainly expressed in the neutrophils, where they mediate neutrophil migration to the site of inflammation. In addition, they are also involved in tumor aggressive growth and metastasis of human malignant melanoma. Structural and biochemical study identified that Reparixin L-lysine salt had non-competitive allosteric interaction with CXCR1 and 2, by which blocking CXCR1 and CXR2 in an inactive conformation, and thus suppressed receptor-induced intracellular signaling cascade and cellular response. When CXCR1 were expressed in L1.2 cells, cell migration induced by 10 nM CXC8 was significantly inhibited by reparixin L-lysine salt. In mouse model, treatment of reparixin L-lysine salt after introduction of injury significantly (15 mg/ kg/ day for 7 days) suppressed secondary degeneration by reducing CXC8-dependent oligodendrocyte apoptosis, migration to the injury site of neutrophils and ED-1-positive cells. Additionally, the level of macrophage-inflammatory protein-2, tumor necrosis factor alpha, interleukin (IL)-6, and IL-1 beta was also reduced, and the proliferation of glial fibrillary acidic protein-positive cells was significantly reduced. In mouse ischemia model, pre-treatment with reparixin reduced the motor deficits, myeloperoxidase activity and IL-1b level. Furthermore, ischemic injury was also attenuated.
CAS No.
266359-93-7
Molecular Weight
429.57
Purity
0.98
Storage
Store at -20°C
Synonyms
Repertaxin L-lysine salt
Targets
CXCR1/CXCR2
Molecular Formula
C20H35N3O5S
Chemical Name
(2S)-2,6-diaminohexanoic acid; (2R)-2-[4-(2-methylpropyl)phenyl]-N-methylsulfonylpropanamide
Solubility
Soluble in DMSO
Shipping Conditions
Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request

Our Products Cannot Be Used As Medicines Directly For Personal Use.

0
Click unfold / close
Inquiry Basket
Delete selected Quote Check Out
Decide to move out of the shopping cart?
Sure No, Back

Please choose product!

< Go Back
You have already added to buy this product